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Objective: To evaluate the cumulative incidence of dyslipidemia and fasting glucose impair-
ment  three years after initiating the ﬁrst antiretroviral (ART) regimen and the association
with  the type of ART regimen in an AIDS outpatient clinic in Brazil.
Methods:  Retrospective cohort of HIV-1 infected patients attending an outpatient HIV clinic
in Vitoria, Brazil, between January/2010 and May/2011. Data, including blood pressure, dys-
lipidemia (high total cholesterol and low HDL-C), fasting glucose, and cardiovascular risk by
Framingham Risk Score were abstracted from medical records from clinic visits six months
prior  and three years after starting ART. We  assessed independent associated factors for
dyslipidemia  using multiple logistic regression.
Results: Four hundred and ninety-eight patients on ART were studied. Median age was 45
years  (interquartile range (IQR): 37–52), and median time since HIV diagnosis was  7.7 years
(IQR:  3.8–10.0). The proportion of patients with dyslipidemia was 22.3% (95% CI: 18.6–25.9%)
36  months after ART initiation. Triglycerides levels >150 mg/dL (55.2% vs. 25.4%, p = 0.021)
and  high fasting glucose (5.8% vs. 2.3%, p = 0.034) were diagnosed more  frequently after
ART  use when compared to baseline values. Multiple logistic regression analysis has showndyslipidemia  to be associated with lopinavir/r use [OR = 1.74 (95% CI: 1.12–2.86)].
Conclusion:  These data show high chance of dyslipidemia after initiation of ART. Long-term
follow-up  will help identify the impact of ART on cardiovascular risk.
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© 20AIDS associated morbidity and mortality has substan-
tially declined since the widespread use of highly active
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Este é um artigo Open Access sob a licençaantiretroviral therapy (ART). Data from Brazil were  among
the  ﬁrst to show this ﬁnding.1 Survival time has increased
lsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDe Misericórdia de Vitoria, Internal Medicine Department, Rua Joao
spinosa2@uol.com.br (L.F.d.S. Pinto Neto).
signiﬁcantly among adult Brazilian AIDS patients, which
demonstrates the beneﬁts of universal access to antiretro-
viral  treatment in a developing country. On the other hand,
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on-AIDS conditions are emerging as signiﬁcant causes of
orbidity  and mortality in the HIV-infected population.
ncreased rates of dyslipidemia and diabetes have been well
ocumented,2,3 with multiple factors accounting for these
ndings,  especially the use of antiretroviral drugs. HIV infec-
ion  itself has been associated with decreases in low-density
ipoprotein (LDL) and high-density lipoprotein (HDL) choles-
erol,  and progressive appearance of hypertriglyceridemia,
ikely related to Interferon alpha (IFN) circulating levels
n  later stage disease.4 A signiﬁcant association between
ecreasing CD4+ cell count and decreasing levels of HDL has
een  described, as well as an association between a history of
IDS-deﬁning  events and higher total cholesterol and triglyc-
ride  concentrations.2
The incidence of diabetes mellitus in HIV-infected men
ith  ART exposure has been shown to be over four times than
hat  seen in HIV-negative men  in the Multicenter AIDS Cohort
tudy,5 after adjusting for body mass index and age. Insulin
esistance has been reported in 13% of HIV-infected patients
fter  a year of ART in a prospective observational cohort
tudy.6 In HIV-infected women, diabetes mellitus incidence
as  been shown to be associated with and longer cumula-
ive  exposure to nucleoside reverse transcriptase inhibitors
NRTI).7
As non-AIDS morbidity has became more  signiﬁcant in
ecent  years, there has been speculation whether HIV infec-
ion  may  be a marker for higher cardiovascular risk, or
xposures unrelated to HIV or ART.8 HIV-infected patients, for
xample, usually have higher smoking rates, and usually need
ssistance  to quit.8–10
Brazilian national guidelines for ART therapy in adults11
ecommend routinely estimation of cardiovascular risk by use
f Framingham Risk Score (FRS). Estimation of the risk for a
ardiovascular event in ten years by the FRS is based on age,
otal  cholesterol, HDL-cholesterol, systolic blood pressure and
moking  status.12 It is designed for patients aged 20 years
nd  older who do not have heart disease or diabetes. As few
tudies  have reported the prevalence of these metabolic com-
lications  in our country,13–15 the aim of our study was to
valuate the cumulative incidence of dyslipidemia and fas-
ing  glucose impairment three years after starting ART and to
nvestigate the association between ART and dyslipidemia in
n AIDS outpatient clinic in Brazil.
ethods
his was  a retrospective cohort study of HIV-1 infected adult
atients  (18 years and older) attending an AIDS outpatient
linic at a University Hospital in Vitória, Brazil, between Jan-
ary  2008 and May  2011. This clinic is the second largest
pecialized Assistance Service (SAS) in the city of Vitoria,
orking since the 1980s and is part of the national public
etwork providing care for HIV-infected patients in Brazil.
Six  hundred and seventy-nine patients were followed in
his  outpatient clinic during the study period. A total of 164
ere  excluded due to unavailability of lipid, glucose or FRS
esults  before treatment, diagnosis of dyslipidemia before
tarting  ART, or lost to follow-up. The majority of the excluded
atients  were aged less than 30 years and thus no lipid proﬁle3;1 7(4):438–443  439
had been requested. The remaining 515 patients were
included.
Demographic, behavioral and clinical data including blood
pressure  measurements, total and HDL cholesterol, fasting
glucose,  and FRS were  abstracted from medical records and
interviews  with all patients, from the last visit (3–6 months)
prior  to and three years following initiation of ART. Infor-
mation  on time on ART, type of ART, smoking status, and
lipid  lowering therapy was also collected. LDL-cholesterol
was calculated using Friedwald’s formula in individuals with
triglycerides  ≤400 mg/dL. When TGL >400, LDL cholesterol was
not  available.
Blood samples were collected after 12 h fasting, according
to  the usual laboratory protocol. All patients included in the
analyses  were  on antiretroviral therapy according to Brazilian
Consensus of Antiretroviral Therapy for Adults guideline.11
Only patients on their ﬁrst ARV regimen were studied. In case
of  ARV regimen change the regimen used for at least 70% of
the  study period was  considered.
Results  of HDL-cholesterol were stratiﬁed as normal or low
(<40  mg/dL in men  and <50 mg/dL in women); total choles-
terol  was  deemed normal or high (>200 mg/dL), LDL cholesterol
as  normal or high (>160 mg/dL), and triglycerides as normal
or  high (>150 mg/dL), according to the Brazilian Cardiology
Society guidelines.16 Impaired fasting glucose and diabetes
were  deﬁned if measurements of fasting glucose levels were
>99  mg/dL and >126 mg/dL, respectively. Patients with low HDL
cholesterol and high total cholesterol levels were  grouped as
having  “dyslipidemia”.
Patient data were entered into a database and analyzed
using SPSS, version 17 for Windows (Chicago, IL, USA).
Standard descriptive analyses were performed including fre-
quency distributions for categorical data and calculation of
medians  and interquartile ranges for continuous variables.
Univariate analyses to assess factors associated with dysli-
pidemia  were  tested using Chi-square and Fisher’s Exact Test,
and  t-test and analysis of variance were used for testing differ-
ences  between means. Odds ratio (OR) was  used as a measure
of  association, estimated with a 95% CI. Independent risk fac-
tors  for “dyslipidemia” were  assessed through multiple logistic
regression  with 15% as the critical p-value for variable entry
and  10% as the criterion for variable elimination.
The study protocol was submitted and approved by the
Escola  de Ciências da Saúde da Santa Casa de Misericordia
institutional review board (# 048/2007).
Results
Five hundred and ﬁfteen (72.1%) patients on ART had lipid
and  glucose data available before and after ARV treatment
and  were  included in the study. Among them 17 (3.3%) had
been  diagnosed with dyslipidemia before ART and were not
included.  Of the remaining 498 patients, 309 (58.9%) were
male  and 301 (60.4%) Caucasian. Median age was  45 years at
2010/2011  visit (interquartile range [IQR]: 37–52), and median
time  since HIV diagnosis was  7.7 years (IQR: 3.8–10.0). The
cohort’s  median age is few years older than the usual age in
our  region as many  young patients had no lipid proﬁle mea-
sured  before ART. The cumulative incidence of dyslipidemia
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Table 1 – Incident dyslipidemia by baseline
demographic, behavioral and clinical characteristics, HIV
patients  on antiretroviral therapy, Vitoria, Brazil (n = 498).
Variables Dyslipidemiaa
n (%)
No dyslipidemia
n (%)
p-Value
Age (years)
18–29 4 (3.6) 24 (6.2) 0.559
30–49  72 (64.9) 239 (62.1)
50  or more 35 (31.5) 122 (31.7)
Gender
Male  62 (55.9) 247 (63.8) 0.149
Female 49 (44.1) 140 (36.2)
Education (years)
Up  to 4 17 (15.3) 39 (10.2) 0.172
More than 4 94 (84.7) 344 (89.8)
Tobacco  use
Yes  34 (31.5) 139 (37.5) 0.306
No  74 (68.5) 232 (62.5)
Nadir  CD4+ (cells/mL)
Up  to 200 68 (61.3) 224  (59.1) 0.742
More  than 200 43 (38.7) 155  (40.9)
Hypertension
Yes  23 (20.7) 71 (18.5) 0.586
No  88 (79.3) 312 (81.5)
Previous diabetes
Yes  3 (2.7) 9 (2.3) 0.945
No  108 (97.3) 375 (97.7)
HCV  infection
Yes 5 (4.5) 24  (6.3) 0.648
No  106 (95.5) 357 (93.7)
a Dyslipidemia: total cholesterol above 200 and HDL bellow 40 for
Table 2 – Incident dyslipidemia by antiretroviral therapy
use,  HIV patients, Vitoria, Brazil (n = 498).
Variables Dyslipidemiaa
n (%)
No  dyslipidemia
n (%)
p-Value
Zidovudine
No 50 (45.0) 187  (48.3) 0.590
Yes  61 (55.0) 200 (51.7)
Lamivudine
No  3 (2.7) 3 (0.8) 0.128
Yes  108 (97.3) 384 (99.2)
Tenofovir
No  62 (55.9) 198 (51.2) 0.383
Yes  49 (44.1) 189 (48.8)
Nevirapine
No  104 (93.7) 349 (90.2) 0.255
Yes  7 (6.3) 38 (9.8)
Efavirenz
No  81 (73.0) 236 (61.0) 0.021
Yes 30 (27.0) 151  (39.0)
Lopinavir/r
No  59 (53.2) 261 (67.4) 0.006
Yes  52 (46.8) 126 (32.6)
Atazanavir/r
No  92 (82.9) 331 (85.5) 0.492
Yes  19 (17.1) 56 (14.5)
Fosamprenavir/r
No  108 (97.3) 382 (98.7) 0.297
Yes 3 (2.7) 5  (1.3)
amen and 50 for women.
was  22.3% (95% CI: 18.6–25.9%) after three years of ART. There
was  no difference between genders.
Table 1 shows demographic, behavioral and clinical charac-
teristics.  There were  no baseline differences between patients
who  developed and who did not develop dyslipidemia on ART.
The  most frequently prescribed nucleoside reverse transcrip-
tase  inhibitors (NRTI) backbone was  lamivudine–zidovudine,
used by 53.1% of patients. Stavudine was  no longer
used, and tenofovir–lamivudine, abacavir–lamivudine and
didanosine–lamivudine were used by the remaining patients.
Lopinavir/r (46.8% vs. 32.6%, p = 0.006) was  associated with
increased  odds of dyslipidemia while efavirenz (27.0% vs.
39.0%,  p = 0.021) was  associated with decreased odds (Table 2).
Median  FRS changed from 1 (IQR: 1–2) before ART to 3 (IQR:
1–9.5)  after therapy (p < 0.001). Table 3 shows the distribution
of  lipids, glucose and FRS before and after ART. All means were
signiﬁcantly  higher in the second measurement.
Triglyceride levels were high in 25.4% of patients before
treatment increasing to 55.2% after treatment (p = 0.021). High
triglyceride  levels were  associated with age higher than 50
years  (36.5% vs. 27.9%, p = 0.039) and with lopinavir/r use
(41.3%  vs. 30.2%, p = 0.009). Impaired fasting glucose was
observed  in 42 patients (8.4%) before ART and in 183 patients
(36.7%)  after ART. Diabetes was  observed in 2.4% (95% CI:
1.0–3.6)  patients before ART and in 5.8% (95% CI: 3.2–7.0) afterDyslipidemia: total cholesterol above 200 and HDL bellow 40 for
men and 50 for women.
three years of ART use (p = 0.034). Impaired fasting glucose
was  also more  frequent in patients aged higher than 50 years
(53.3%  vs. 30.8%, p = 0.010), and in patients co-infected with
hepatitis  C virus (16.7% vs. 5.6%, p = 0.032). No association was
found  with CD4 nadir.
In  the ﬁnal regression model, lopinavir/r use [OR = 1.74 (95%
CI:  1.12–2.86)] remained signiﬁcantly and independently asso-
ciated  with dyslipidemia (high cholesterol and low HDL-C)
after  ART (Table 4).
Discussion
Low HDL-cholesterol, deﬁned as HDL <40 mg/dL for men  and
<50  mg/dL for women was  found in 58.1% of HIV-infected
patients prior to initiating ART. Although a modest but sig-
niﬁcant  increase on HDL cholesterol mean was  observed after
ART,  the proportion of patients with low HDL remains almost
the  same as it was  before ART. These results are consis-
tent  with advanced HIV disease.17 Rose et al. suggested that
HIV  infection is associated with modiﬁed HDL metabolism
re-directing cholesterol to the apo B-containing lipoproteins
and  likely reducing the functionality of reverse cholesterol
transport.18 Higher activity of cholesterol ester transfers pro-
tein  (CETP) correlated negatively with levels of HDL-C and is
probably associated with higher risks of coronary artery dis-
ease  especially in patients with hypertriglyceridemia.19
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Table 3 – Serum lipid and fasting glucose levels before and after ART initiation, HIV patients Vitoria, Brazil.
Before ART mean (SD) After ART mean (SD) p-Value
Cholesterol (mg/dL) 163.0 (36.3) 194.9 (41.3) 0.001
HDL-C (mg/dL) 41.8 (12.9) 44.5 (13.1) 0.001
LDL-C (mg/dL) 93.2 (29.7) 113.8 (35.4) 0.001
Triglycerides (mg/dL) 138.1 (81.3) 191.8 (76.0) 0.001
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AFasting glucose (mg/dL) 85.2 (16.7) 
FRS median (IQR) 1 (1–2) 
We  also observed high triglyceride levels in 55.2% of our
atients  after treatment initiation, a twofold higher propor-
ion  than that observed prior to ART (25.4%). Ceccato et al.
lso  reported a high prevalence of hypertriglyceridemia and
ow  HDL (32.4%) among HIV patients after ART in a refer-
nce  center in Brazil.20 High cholesterol levels were observed
mong  45.8% of treated patients, threefold higher than what
as  observed before treatment and it was  associated with
opinavir/r  use. A meta-analysis of 15 clinical trials enrolling a
otal of 6368 patients, designed to evaluate effects of ﬁrst line
ntiretroviral  therapy on lipids levels, showed that lopinavir/r
nd  fosamprenavir/r were  associated with greater elevations
n  total cholesterol and triglycerides.21 Our ﬁndings are con-
istent  with a small effect of ART on absolute changes in HDL
evels  from baseline to three years of follow up.
Hypertriglyceridemia in untreated HIV-infected patients
ay  be a consequence of a systemic inﬂammatory response
gainst  persistent viral infection and it correlates with serum
nterferon-alpha levels.22 In Brazil, lopinavir/r is the ﬁrst
hoice  protease inhibitor, thus highly used by our patients.
thers  authors have shown that four weeks of lopinavir/r use
re  enough to signiﬁcantly raise lipid levels.23 Brazilian treat-
ent  guidelines are currently being revised, so other protease
nhibitors  may  be added as ﬁrst choice options, especially
iven knowledge of associated elevations in lipids.
Impaired fasting glucose was  present in a signiﬁcantly
igher proportion of patients after ART initiation. A study
as  shown a modest association between untreated HIV and
nsulin  resistance, mediated by inﬂammatory cytokines.24
owever, Blanco et al. have reported that impaired glucose tol-
rance in treatment-experienced patients is higher (10–25%)
han  among treatment-naïve patients (5–10%), especially in
hose receiving protease inhibitors.25 Some evidence links
rotease  inhibitors to the pathogenesis of insulin resistance,
ith  acute inhibition of GLUT4-mediated glucose transport,
26nd  defective insulin signaling. We  did not ﬁnd an associa-
ion  of impaired glucose tolerance or diabetes to any speciﬁc
RT  type, possibly due to the modest sample size.
Table 4 – Variables independently associated with
dyslipidemia, HIV patients on antiretroviral therapy,
Vitoria, Brazil (n = 494).
Variables OR 95% CI p-Value
Sex (male vs. female) 1.47 0.95–2.29 0.088
Education (up to 4 vs. more than 4) 1.53 0.82–2.87 0.185
Lamivudine (yes vs. no) 0.28 0.05–1.45 0.130
Efavirenz (yes vs. no) 0.76 0.44–1.31 0.314
Lopinavir/r (yes vs. no) 1.68 1.12–2.2.78 0.04098.4 (21.1) 0.001
3 (1–9.5) 0.001
Our results underscore the association between impaired
fasting glucose and elevated triglycerides with age higher than
50  years old. Median age of our patients was  only 45 years
and  these metabolic disturbances shall get worse as this pop-
ulation  age. Projections of global mortality from the World
Health  Organization predict that ischemic heart disease will
be  among the ﬁrst three causes of death in the HIV popula-
tion  in low income countries.27 Active prevention, immediate
diagnosis and management of cardiovascular risk factors, like
the metabolic disturbances here described, must be standard
of  care in outpatient clinics.
We  have not found discrepant variations in median FRS
before  and after treatment. Although the FRS has not been
speciﬁcally validated in HIV-positive patients, it has been
applied  since no other option is already available. Nev-
ertheless, some speculate that it may  underestimate the
cardiovascular risk, especially in smokers.28 All but two of our
patients  on statin therapy were using pravastatin 40 mg/day.
Pravastatin is a weak statin, and most of the time it was
prescribed it was not available for the patients in need. Rosu-
vastatin  has been proven to be more  effective in HIV patients29
and may  further improve lipid proﬁles in our patients, when
available.  Seventy-two patients were  prescribed statins, but
with  so irregular use, that the impact on lipids could not be
evaluated.
We  observed a high prevalence of tobacco use among
our  patients (36%) that varies little (and this value does
not  change signiﬁcantly) between the two Framingham time
points  (before and after ART). Tobacco use in our patient pop-
ulation  was  more  than one and half times higher than the
observed  use among the adult population in Vitoria30 and even
higher  than the observed smoking habit among HIV-infected
patients in Sao Paulo.31 We need to enhance our efforts to
assist  HIV-infected patients to quit smoking.
We acknowledge other limitations of the study: retrospec-
tive  cohort study has limitations to analyze the effects of
therapy  in HIV infected patients. The issue of whether ART
affects  dyslipidemia is best addressed by prospective studies
with  HIV-infected patients either receiving or initiating ther-
apy.  Also, we  did not have access to data regarding excluded
patients and it might have caused bias because we  cannot say
if  these patients are different or how different they are from
the  included patients. Another limitation is that given the low
prevalence  of some risk factors in this sample, it is possible
that  the number of patients studied was  not sufﬁcient to ﬁnd
statistical  association between some independent variables
and  dyslipidemia.In  conclusion, we found frequent lipid and glucose pertur-
bations in HIV-infected patients on ART, which may  worsen
over  time. Infectious disease doctors, despite still looking at
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HIV viral load need to act as primary care physicians strongly
encouraging their patients to quit smoking, pursuing the best
goal  on blood pressure control and taking a closer look on
lipids  and glucose levels. This must be a priority in the care
of  those patients especially as this population ages. Brazil-
ian  outpatient clinics need to focus more  on those controls
although increasing prevalence of cardiovascular risk factors
will  overshadow the amazing beneﬁts of antiretroviral ther-
apy.
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